Stay updated with breaking news from Judith Teumer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQS-News: Apogenix AG / Key word(s): Scientific publication Apogenix AG: Apogenix’ new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model 01.06.2023 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. Apogenix’ new CD40 agonist...
EQS-News: Apogenix AG / Key word(s): Study/Study results Apogenix' Partner CANbridge Announces 67 % Five-Year Overall Survival Rate Compared to 8.2 % in Institutional Database With Asunercept
EQS-News: Apogenix AG / Key word(s): Study resultsApogenix’ Asunercept Demonstrates Efficacy in Phase II Trial for the Treatment of Hospitalized COVID-19 Patients 19.10.2022 / 10:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Press ReleaseApogenix’ Asunercept Demonstrates Efficacy i...